| Dr Daniel Ludvic Maryland, MD | |
|
332 East Central Entrance, Duluth, MN 55811-5514 | |
| (218) 722-5871 | |
| Not Available |
| Full Name | Dr Daniel Ludvic Maryland |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 332 East Central Entrance, Duluth, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427015973 | NPI | - | NPPES |
| 74582MA | Other | MN | BLUE CROSS BLUE SHIELD AF |
| 31271000 | Medicaid | WI | |
| HP49310 | Other | HEALTH PARTNERS | |
| 0806038 | Other | MEDICA | |
| 112146 | Other | MN | UCARE |
| 5137060 | Other | FIRST HEALTH | |
| 785001 | Other | MN | PREFERRED ONE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 14953 (Minnesota) | Primary |
| 207W00000X | Ophthalmology | 15070020 (Wisconsin) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Ludvic Maryland, MD 332 East Central Entrance, Duluth, MN 55811-5514 Ph: (218) 722-5871 | Dr Daniel Ludvic Maryland, MD 332 East Central Entrance, Duluth, MN 55811-5514 Ph: (218) 722-5871 |
News Archive
Some flowers have a remarkable and previously unknown ability to bounce back after injury, according to a new study
Lightpoint Medical, an innovative medical device company specializing in imaging technologies announced today that it has received an R01 grant of $2.6M million from the US National Cancer Institute. The funding will support clinical trials of Lightpoint's EnLight™ molecular imaging technology in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center.
The first genome-wide association study of an infectious disease, conducted by an international group of researchers through the Center for HIV/AIDS Vaccine Immunology (CHAVI), has yielded a new understanding of why some people can suppress virus levels following HIV infection.
GTx, Inc. announced that Ostarine (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator, MK-3984, in postmenopausal women. The data were presented yesterday at the 2010 Annual Meeting of the Endocrine Society. GTx is developing its lead SARM, Ostarine, for the treatment of cancer induced muscle wasting (cancer cachexia).
A team of US scientists found that the enzyme lysyl oxidase (LOX) alters the structure of collagen - the major component of connective tissue - in the cells surrounding the growing tumour.
› Verified 7 days ago
Dr. Luke Tae Jong Moore, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-8364 | |
Jenny Yunjie Wang, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 502 E 2nd St, Duluth, MN 55805 Phone: 218-786-8364 | |
Robert W Hollenhorst, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 5007 Matterhorn Dr, Duluth, MN 55811 Phone: 218-720-3553 Fax: 218-786-9375 | |
Charles Earl Ahrens, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4190 Loberg Ave, Duluth, MN 55811 Phone: 218-249-4600 Fax: 218-249-4666 | |
Dr. Kevin William Treacy, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 324 W Superior St, 800 Medical Arts, Duluth, MN 55802 Phone: 218-249-3570 Fax: 218-722-8582 | |
Joseph Davis Morehouse, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-3937 |